ArticleThe journal of headache and pain2022
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study.
Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interictal burden in migraine: a systematic review of conceptual domains and measurement properties of instruments.The journal of headache and pain · 2026Pooled it
- Enhancing chronic migraine preventive therapy: low-level 810 nm laser acupuncture as an add-on treatment for patients with unsatisfactory pharmacological effect, a pilot single-blind randomized controlled trial.BMC complementary medicine and therapies · 2024Trial
- Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.The journal of headache and pain · 2022Trial
- Cyberchondria in Migraine: The Role of Disease Burden and Medication Overuse.European journal of pain (London, England) · 2026Article
- Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.International journal of pharmaceutics · 2026Article
- The Interictal State of Migraine: Understanding the Hidden Burden Between Attacks.Current pain and headache reports · 2026Review
- Adapting to life with chronic migraine: a qualitative study of lived experiences among multi-ethnic Asian patients.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Factors Impacting the Telephone Follow-Up Response Rate in Patients With Migraine Without Aura: A Cross-Sectional Study of 1299 Females.Pain research & management · 2026Article
- Trends in the Disease Burden of Migraine Among Women of Reproductive Age (15-49 Years) in Low- and Middle-Income Countries, 1990-2023.International journal of women's health · 2026Article
- The Social Life of Migraine: A Meta-Ethnography of Lived Experience in Adults With Migraine.Health services insights · 2026Review
- Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.The journal of headache and pain · 2025Article
- Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine.The journal of headache and pain · 2025Observational
- Identifying Hidden Disability in Migraine Patients Using the Migraine Interictal Burden Scale-4.Cureus · 2025Article
- Neuro-ophthalmology and migraine: visual aura and its neural basis.International journal of emergency medicine · 2025Review
- Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease.Journal of managed care & specialty pharmacy · 2025Article
- Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.Frontiers in neurology · 2025Article
- The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective.Frontiers in neurology · 2025Article
- Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention.The journal of headache and pain · 2024Article
- Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.The journal of headache and pain · 2024Observational
- Decoding pain through facial expressions: a study of patients with migraine.The journal of headache and pain · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on patients' health-related quality of life (HRQL). Acute and preventive treatments may lift the burden of the disease, but they often have unwanted side effects and limited effectiveness. The objective of this study was to understand the interictal burden of migraines, from the patient perspective, and to explore patient experience with migraine treatments.
methodsParticipants (n=35) with a self-reported diagnosis of migraine were recruited in the US, UK and Canada, including a subgroup of patients who had taken calcitonin gene-related peptide monoclonal antibody (CGRP mAb) treatment for at least three months. Participants completed a background questionnaire, followed by a semi-structured interview via telephone or video call. The interviews explored patients' migraine symptoms, perception of interictal burden and treatment experience. The interview transcripts were analysed using thematic analysis.
resultsThe most reported migraine symptom was migraine pain, followed by aura, sensory sensitivity and nausea. Most participants reported interictal impact on HRQL, lifestyle changes they made to avoid triggers or in anticipation of an attack, impacts on work, career, daily activities and relationships. Emotional impacts were reported by all participants, including anger, depression, anxiety and hopelessness. Many participants who took preventive treatments reported improvements in HRQL and functioning but still experienced breakthrough attacks. Among patients who took CGRP mAbs, participants noted varying consistency of treatment effectiveness between treatment administrations.
conclusionThis study detailed the additional HRQL impact of migraine in-between migraine attacks and described the unmet need for effective treatment options to prevent and mitigate migraine attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.